


GENE FAMILY TARGETED MOLECULAR DESIGN

EDITED BY
KAREN E. LACKEY



 WILEY

CONTENTS

Preface	xi
Contributors	xv
1 Drug Discoveries by Gene Family	1
<i>Karen E. Lackey</i>	
1.1 General Drug Discovery Components,	1
1.2 Further Reading for Expert Knowledge,	10
References,	13
2 G-Protein-Coupled Receptors	15
<i>Stephen L. Garland and Tom D. Heightman</i>	
2.1 Introduction,	15
2.2 GPCR Structure and Function,	18
2.2.1 Subfamilies,	18
2.2.2 Structural Information and Homology Models,	22
2.2.3 Mechanisms of Receptor Modulation,	27
2.2.4 G-Protein Coupling and Assay Formats,	33
2.3 Challenges Facing the Area of GPCR Drug Design,	35
2.3.1 Hit Generation Strategies: Chemogenomics and Privileged Structures,	36
2.3.2 Case History: Calcitonin Gene-Related Peptide Receptor Antagonist (MK-0974, telcagepant),	40
2.3.3 Case History: Mixed Dopamine/Serotonin Receptor Antagonist As An Atypical Anti-Psychotic,	43

- 2.3.4 Case History: Chemokine Receptor CCR5 Antagonist Maraviroc (CelsentriTM), 45
- 2.3.5 Case History: The Discovery of Cinacalcet (Sensipar[®]/Mimpara[®]), a CaSR-Positive Allosteric Modulator, 47
- 2.4 Conclusions and Outlook, 49
- References, 50

3 Ion Channels Gene Family: Strategies for Discovering Ion Channel Drugs **53**

Maria L. Garcia and Gregory J. Kaczorowski

- 3.1 Introduction, 53
- 3.2 Ion Channel Subfamily Descriptions, 54
 - 3.2.1 Voltage-Gated Ion Channels, 54
 - 3.2.2 Inward Rectifier Potassium Channels, 55
 - 3.2.3 Voltage-Gated Potassium Channels, 58
 - 3.2.4 Calcium-Activated Potassium Channels, 61
- 3.3 Structure of Potassium Channels, 64
- 3.4 Criteria for Selection of Targets and Establishing Screens, 68
- 3.5 A Case Study in Ion Channel Drug Discovery, 70
- 3.6 Perspective on Ion Channels as Drug Targets, 77
- References, 78

4 Integrins **85**

David D. Miller

- 4.1 Introduction, 85
- 4.2 Integrin Inhibitor Discovery, 89
 - 4.2.1 Cyclic Peptides, 91
 - 4.2.2 Peptidomimetic Chemistry, 92
 - 4.2.3 Preferred Peptidomimetic Fragments, 102
 - 4.2.4 I-Domain Integrin Inhibitors, 103
 - 4.2.5 Protein Structure-Based Design, 110
- 4.3 Challenges—Past and Future, 112
- References, 113

5 Strategies for Discovering Kinase Drugs **119**

Jerry L. Adams, Paul Bamborough, David H. Drewry, and Lisa Shewchuk

- 5.1 Introduction, 119
- 5.2 Protein Kinase Structural Features, 120
- 5.3 Generating and Optimizing Kinase Inhibitors, 124
 - 5.3.1 ATP Binding Pocket, 124
 - 5.3.2 Non-ATP Binding Pockets, 133

5.4	Establishing Screens for Understanding Kinase Activity and Selectivity, 135	
5.5	Case Studies of Successful Kinase Drug Discovery, 140	
	References, 150	
6	Protease-Directed Drug Discovery	159
	<i>Richard Sedrani, Ulrich Hommel, and Jörg Eder</i>	
6.1	Introduction, 159	
6.2	Aspartic Proteases, 162	
6.2.1	HIV Protease Inhibitors, 164	
6.2.2	Renin, 166	
6.3	Metalloproteases, 168	
6.3.1	Angiotensin-Converting Enzyme, 168	
6.3.2	Matrix Metalloproteases, 170	
6.4	Serine Proteases, 175	
6.4.1	Dipeptidyl Peptidase 4 (DPP4), 176	
6.4.2	Trypsin-Like S1 Serine Proteases of the Coagulation Cascade, 179	
6.5	Cysteine Proteases, 183	
6.5.1	Cathepsin K, 184	
6.5.2	Caspases, 188	
6.6	Perspective on Proteases as Drug Targets, 190	
	References, 191	
7	Small-Molecule Inhibitors of Protein–Protein Interactions: Challenges and Prospects	199
	<i>Adrian Whitty</i>	
7.1	Introduction, 199	
7.2	Structure and Properties of PPI, 201	
7.2.1	Constitutive versus Transient PPI, 201	
7.2.2	Physicochemical Properties and Residue Propensities of PPI, 202	
7.2.3	Binding Energetics and “Hotspots”, 204	
7.3	Structural and Physicochemical Challenges to Inhibiting PPI with Small Molecules, 207	
7.3.1	Key Role of Adaptivity at the Interface, 210	
7.3.2	Constraints of “Drug-Like” Chemical Space, 212	
7.4	Identifying Hits and Leads Against PPI Targets, 213	
7.4.1	Fragment-Based Screening, 214	
7.4.2	Validating and Optimizing Hits and Leads, 218	
7.5	Assessing the Druggability of New PPI Targets, 225	
	References, 227	

8 Transporters 235*Anne Hersey, Frank E. Blaney, and Sandeep Modi*

- 8.1 Introduction, 235
- 8.2 Methodologies in Transporter Drug Design, 239
 - 8.2.1 Structure-Based Methods, 239
 - 8.2.2 Ligand-Based Methods, 245
- 8.3 Therapeutic Transporter Targets in Drug Discovery, 248
 - 8.3.1 Vacuolar ATPases, 248
 - 8.3.2 Gastric (P-) ATPases, 251
 - 8.3.3 Neurotransmitter Transporters as Drug Targets, 252
- 8.4 Transporters as Liability Targets, 256
 - 8.4.1 P-glycoprotein, 259
 - 8.4.2 OATP1B1, 261
- 8.5 Application of Methods for Designing Interactions with Liability Targets, 262
- 8.6 Perspective, 267
- References, 267

9 Nuclear Receptor Drug Discovery 275*Hiroyuki Kagechika and Aya Tanatani*

- 9.1 Introduction, 275
- 9.2 Nuclear Receptor Superfamily and Their Functions, 276
- 9.3 Agonism and Antagonism in Nuclear Receptor Functions, 279
 - 9.3.1 AR Antagonists Effective Toward Mutated Receptors, 283
 - 9.3.2 VDR Agonists and Antagonists, 286
 - 9.3.3 Carboranes as Novel Hydrophobic Pharmacophores, 290
- 9.4 Medicinal Chemistry of Retinoid Nuclear Receptors, 293
 - 9.4.1 Retinoid and Their Nuclear Receptors, 293
 - 9.4.2 Retinobenzoic Acids, 300
 - 9.4.3 RXR-Selective Ligands, 306
- 9.5 Clinical Application of Retinoids, 309
- 9.6 Perspective, 311
- References, 312

10 Summary and Comparison of Molecules Designed to Modulate Druggable Targets in the Major Gene Families 317*Karen E. Lackey*

- 10.1 Target Class Concept, 317
- 10.2 Summary of the Unique Features of Each Target Class, 318
 - 10.2.1 GPCR/7TM, 318
 - 10.2.2 Ion Channels, 320
 - 10.2.3 Integrins, 322

CONTENTS

ix

- 10.2.4 Kinases, 323
- 10.2.5 Proteases, 324
- 10.2.6 Protein–Protein Interactions, 325
- 10.2.7 Transporters, 327
- 10.2.8 Nuclear Receptors, 328

10.3 Perspective, 330

References, 331

Appendix

333

Index

341